Biotech Bankruptcies Face IP Challenges

Law360, New York (May 21, 2007, 12:00 AM EDT) -- Sticking a price tag on a life sciences or biotechnology company’s intellectual property can be a tall order, but the challenge becomes even greater when that company files for bankruptcy protection.

With an industry that often involves IP that is tied up in a developmental stage or that awaits federal approval, it is no wonder bankruptcy and IP attorneys have their work cut out for them in these types of bankruptcy cases.

“When taking a debtor through Chapter 11 while the company is in phase 3...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.